Cancer Research  09 AM Call for Abstracts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 49, 983-990, February 15, 1989]
© 1989 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bízik, J.
Right arrow Articles by Vaheri, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bízik, J.
Right arrow Articles by Vaheri, A.

Clonal Variation in the Production of Tumor-associated {alpha}2-Macroglobulin in a Malignant Human Melanoma and Association with Growth Stimulation1

J. Bízik, A. Lizo^nová, M. Grófová2, J. Matoska, J. F. Doré, S. Bertrand, M. Blasko and A. Vaheri

Cancer Research Institute of the Slovak Academy of Sciences [J. B., A. L., M. G., J. M., M. B.], 81232 Bratislava, Czechoslovakia; Laboratoire d'Immunologie et de Cancérologie Expérimentale [J. F. D., S. B., J. B.], Inserum U 218, Centre Léon Bérard, 69373 Lyon, France; and Department of Virology, University of Helsinki [A. V.], 00290 Helsinki, Finland

{alpha}2-Macroglobulin ({alpha}2-M) is known as a wide-spectrum proteinase inhibitor and to bind covalently certain growth factors. We have previously characterized tumor-associated {alpha}2-M synthesized and secreted by human tumor cell lines. Of the cell lines studied, the melanoma cell line HMB-2 produced the largest amount of this glycoprotein. Immunofluorescence staining of cultured HMB-2 cells suggested that the cell population is heterogeneous with respect to {alpha}2-M production. We have now isolated clones from the parental HMB-2 cells and characterized eight representative ones in detail. They varied considerably in the quantity of {alpha}2-M secreted, from 4.2 to 46.5% of total protein. No relationship between the production of {alpha}2-M by these clones and their pigmentation or tumorigenicity in nude mice was found. However, statistically there was a strong correlation between the modal chromosome number and population doubling time (r2 = 0.88, P < 0.001) and also between the modal chromosome number and {alpha}2-M production (r2 = 0.73, P < 0.01). The growth rate of the clones correlated with the level of {alpha}2-M in culture medium (r2 = 0.69, P < 0.01). Clones with lower {alpha}2-M production had a proportionally shorter population doubling time than the clones with intermediate or high production. Northern hybridization indicated quantitative variation in the {alpha}2-M mRNA expressed by the parental cells and the clones, that was comparable but not identical with the quantity of {alpha}2-M in the respective culture media; both parental cells and clones expressed platelet-derived growth factor A-chain mRNAs with little difference in levels. Serum-free medium from low {alpha}2-M producer clones stimulated normal stationary fibroblasts significantly more than clones producing intermediate or high amounts of {alpha}2-M. {alpha}2-M decreased and anti-{alpha}2-M IgG increased the stimulation. These results suggest that production of tumor-associated {alpha}2-M is related to both autocrine and paracrine growth-stimulating activity of the tumor cells.

1 The project was supported by funds partly provided by the International Cancer Research Data Bank Program of the National Cancer Institute, NIH (US), under Contract N01-CO-65341 (International Cancer Research Technology Transfer-ICRETT), and partly by the International Union against Cancer; and funds from the Association pour la Recherche sur de Cancer, Villejuif, France.

2 To whom requests for reprints should be addressed, at the Cancer Research Institute, Cs. armády 21, 81232 Bratislava, Czechoslovakia.

Received 4/14/88. Revised 8/ 9/88. Accepted 11/11/88.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1989 by the American Association for Cancer Research.